Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation

Brain Res Bull. 1996;41(2):93-6.

Abstract

Desipramine (DMI, 15 mg/kg, s.c.) decreased [3H]CGP-12177-labelled cortical beta-adrenoceptor density (Bmax) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the beta-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of beta-adrenoceptor Bmax (-15%; p < 0.01). Acute treatment with amitryptiline (10), clorgyline (1), fluoxetine (10), nomifensine (10) or maprotiline (20) had no significant effect on [3H]CGP-12177-labelled beta-adrenoceptors, suggesting that rapid down-regulation may not be a general property of antidepressant drugs. None of the antidepressants altered the Bmax of [3H]ketanserin-labelled 5-HT2A receptors on acute treatment. These results show that beta-adrenoceptor down-regulation by clenbuterol and DMI is not dependent on chronic treatment and may, therefore, be a poor correlate of the gradual onset of therapeutic efficacy seen clinically with antidepressant drugs.

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology*
  • Adrenergic beta-Agonists / pharmacology*
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Animals
  • Antidepressive Agents, Second-Generation / pharmacology
  • Clenbuterol / pharmacology*
  • Desipramine / pharmacology*
  • Down-Regulation / drug effects*
  • Male
  • Propanolamines / pharmacokinetics
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, beta / biosynthesis
  • Receptors, Adrenergic, beta / drug effects*
  • Receptors, Serotonin / biosynthesis
  • Receptors, Serotonin / drug effects

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Antidepressive Agents, Second-Generation
  • Propanolamines
  • Receptors, Adrenergic, beta
  • Receptors, Serotonin
  • CGP 12177
  • Desipramine
  • Clenbuterol